Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- New Ninlaro Production Facility in Ireland Breaks Ground
June 2, 2017
- Eisai, Broad Institute Ink New Deal on Malaria Medicine
June 2, 2017
- Sawai’s Upsher-Smith Acquisition Completed
June 2, 2017
- PeptiDream, Shionogi, Sekisui Chemical to Form CMO for Specialty Peptide
June 2, 2017
- Once-Every-4-Week Administration of Praluent Meets Primary Endpoint in PIII Study in Japanese Patients: Sanofi
June 2, 2017
- FY2016 Earnings Roundup - 5: Drug Makers Anticipate Nearly Flat Growth in FY2017; Mid-Term Outlook Unclear
June 2, 2017
- Ono Licenses MEK Inhibitor, BRAF Inhibitor from Array Biopharma
June 1, 2017
- NBI, Kobe Univ. Tie Up to Develop Novel Treatments for Insulin-Resistant Disorders
June 1, 2017
- Daiichi Sankyo to Commercialize Opioid Analgesic in US, Eying Launch during FY2017
June 1, 2017
- FY2016 Earnings Roundup - 4: Average Productivity per Sales Rep Up Only 14 Million Yen in 6 Years
June 1, 2017
- FY2016 Earnings Roundup - 3: Price Battle Batters Generic Makers, 3 Majors’ Profit Rate in Single-Digits
May 31, 2017
- FY2016 Earnings Roundup - 2: Entyvio Robust, Xtandi Treads Water as Global Brands Underpin Revenue
May 30, 2017
- Sunovion’s COPD Med Slapped with FDA Complete Response Letter
May 30, 2017
- Sumitomo Dainippon to Adopt IFRS
May 30, 2017
- Bayer Fails to Report 12 Side Effect Cases for Xarelto, Scandal Probe Finds
May 29, 2017
- Zytiga Filed for Earlier Prostate Cancer Treatment
May 29, 2017
- FY2016 Earnings Roundup - 1: Japan’s Growth Potential Falters Despite 2.2% CAGR from FY2010
May 29, 2017
- Teijin Pharma Licenses Tau-Targeting Alzheimer’s Drug to Merck
May 29, 2017
- Over 50% of Doctors Don’t Allow Gx Switches for Certain Products: Survey
May 26, 2017
- TS-1 Generics Now Have Same Indications as Originator
May 25, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…